Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Trial Details

NCT ID
NCT05489211
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Datopotamab deruxtecan (Dato-DXd)
  • Capecitabine
  • 5-Fluorouracil
  • Volrustomig
  • Carboplatin
  • Bevacizumab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Muncie, Indiana, United States|40.19338,-85.38636
  • Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

  • Male and female, ≥ 18 years
  • Documented advanced or metastatic malignancy
  • Eastern Cooperative Oncology Group performance status of 0 or 1 with no deterioration over the 2 weeks prior to baseline or day of first dosing
  • All participants must provide a tumour sample for tissue-based analysis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →